Most Read Articles
5 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 4 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Dr. Wong Soon Tee, Yesterday
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
2 days ago
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.

Sorafenib-pravastatin combo does not improve survival in hepatocellular carcinoma

20 Aug 2019

The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.

A total of 312 patients with advanced HCC and who were naïve to systemic treatment were assigned to receive sorafenib either in combination with pravastatin (n=162; median age, 68 years; 96.3 percent male) or alone (n=161; median age, 68 years; 88.2 percent male). The primary study outcome was overall survival (OS), while progression-free survival (PFS), safety, time to treatment failure, quality of life and time to progression were secondary endpoints.

Patients who received the combination treatment survived for a median period of 34.7 months. This outcome was not significantly better than in those who were given sorafenib alone (median, 36.1 months).

A total of 269 deaths were reported, 135 of which occurred in the combination arm. The resulting OS rates were comparable between the two treatment arms (sorafenib alone vs combination: 44.9 percent vs 47.2 percent; hazard ratio [HR], 1.00, 95 percent CI, 0.79–1.28; p=0.975).

The same was true for 1-year PFS (16.5 percent vs 18.8 percent; HR, 1.00, 0.80–1.25; p=0.986), time to progression (28.3 percent vs 26.9 percent; HR, 1.06, 0.80–1.38; p=0.698) and time to treatment failure (19.3 percent vs 25.2 percent; HR, 0.92, 0.73–1.16; p=0.502).

Multivariate analysis further confirmed these findings, showing that only scores in the Cancer of Liver Italian Program were significant predictors of survival (HR, 2.54, 1.88–3.44; p<0.0001) and that the assigned treatment was not (HR, 0.94, 0.71–1.25; p=0.688).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 4 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Dr. Wong Soon Tee, Yesterday
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
2 days ago
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.